Log In
BCIQ
Print this Print this
 

IRN-SRN, irinotecan (BA-018)

Also known as: Oral irinotecan sustained release nanoparticles

  Manage Alerts
Collapse Summary General Information
Company Onxeo S.A.
DescriptionOral formulation of irinotecan encapsulated into nanoparticles
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationColorectal cancer
Indication DetailsTreat colorectal cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today